Phase Ib/II Study of MEDI4736 evaluated in different combinations in Metastatic Pancreatic Ductal Carcinoma

Trial Identifier: D4198C00003
Sponsor: AstraZeneca
NCTID:: NCT02583477
Start Date: March 2016
Primary Completion Date: July 2018
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
English Translation

Trial Locations

Country Location
United Kingdom Cambridge, United Kingdom, CB2 0QQ
United Kingdom Glasgow, United Kingdom, G12 0YN
United Kingdom London, United Kingdom, W12 0NN
United Kingdom London, United Kingdom, SE1 9RY
United Kingdom Manchester, United Kingdom, M20 4BX
United Kingdom Wirral, United Kingdom, CH63 4JY
United States of America, CA Stanford, CA, United States of America, 94305
United States of America, NY Rochester, NY, United States of America, 14642
United States of America, PA Pittsburgh, PA, United States of America, 15232